A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein
Melanoma is a highly aggressive tumor with a poor prognosis, and half of all melanoma patients harbor BRAF mutations. A BRAF inhibitor, vemurafenib (PLX4032), has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat advanced melanoma patients with B...
Saved in:
Main Authors: | Hui Li (Author), Juan Liu (Author), Xiaojuan Xiao (Author), Shuming Sun (Author), Hui Zhang (Author), Yibin Zhang (Author), Weihua Zhou (Author), Bin Zhang (Author), Mridul Roy (Author), Hong Liu (Author), Mao Ye (Author), Zi Wang (Author), Feng Liu-Smith (Author), Jing Liu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cutaneous side-effects during therapy of melanoma by vemurafenib
by: Anna Ankudowicz, et al.
Published: (2015) -
The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
by: Hongmei Cui, et al.
Published: (2021) -
Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
by: Rakan Radi, et al.
Published: (2022) -
The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B
by: Shi-Long Jiang, et al.
Published: (2021) -
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy
by: Chung-Pu Wu, et al.
Published: (2014)